On the 24th of October, a CPMS Webinar will be held at 14:00 CET
The topic of the Webinar is CPMS upcoming changes.
Webinar “New therapeutic targets for the treatment of pancreatic neuroendocrine” – cancelled
Due to unforeseen circumstances we will need to cancel the Webinar “New therapeutic targets for the treatment of pancreatic neuroendocrine tumours”, that was scheduled on October 10th at 16:00-17:00 CET. A new date will be announced as soon as possible.
Newsletter September 2019
The first call for new members to join existing 24 ERNs is now open.
The first call for new members to join existing 24 ERNs is now open until 30 November 2019.
For more information how to apply and join Endo-ERN click here
Disorders of phosphate imbalance: a dysregulation of the FGF23 endocrine system
The National Coordinators of EndoERN, BondERN and ERKnet strongly aimed for this multidisciplinary meeting which brings together national and international experts on hypophosphatemia XLH to discuss its management and for its greater dissemination.
July & August newsletter
The July & August-edition of the Endo-ERN newsletter is out now! The call for new members to join the ERN will launch soon, 11 new Affiliated Partners joined the European Reference Network, information about the upcoming events and much more!
Click here for the newsletter
Wolfram syndrome scientific and family meeting in Cardano al Campo (Varese, Italy)
On behalf of the “Associazione Gentian” the “Wolfram Syndrome Italy Association” we cordially invite you to the national scientific and family meeting to be held in Cardano al Campo (Varese, Italy), 21 September 2019. The meeting brings together Italian scientists, families and patients and will be focused on Wolfram syndrome. You will have the unique opportunity to network with colleagues and experts in the field.
Please click here for the program.
Newsletter July – August 2019
Medical treatment for MCT8 deficiency
Background Deficiency of the thyroid hormone transporter monocarboxylate transporter 8 (MCT8) causes severe intellectual and motor disability and high serum tri-iodothyronine (T3) concentrations (Allan–Herndon–Dudley syndrome). This chronic thyrotoxicosis leads to progressive deterioration in bodyweight, tachycardia, and muscle wasting, predisposing affected individuals to substantial morbidity and mortality. Treatment that safely alleviates peripheral thyrotoxicosis and reverses cerebral hypothyroidism is not yet available. We aimed to investigate the effects of treatment with the T3 analogue Triac (3,3′,5-tri-iodothyroacetic acid, or tiratricol), in patients with MCT8 deficiency.
